Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03171402 · ClinicalTrials.gov registry record
Astringency and Bitterness Perception
A clinical trial, sponsored by Purdue University.
- Completed
- Registry status
- 92
- Enrollment target
NCT03171402: Completed study, sponsored by Purdue University.
NCT03171402 is a clinical trial that has completed, run by Purdue University. The registered enrollment target is 92 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03171402 has completed, sponsored by Purdue University.
- COMPLETED
- Registry status
- 92 participants
- Enrollment target
Study Summary
The investigators are conducting a study to better understand how the average consumer differentiates between bitter and astringent sensations, both of which are typically unpleasant sensations characteristic of some healthy foods. Astringency is the dry/rough sensation elicited by foods such as green bananas and some wines. Although trained scientists can differentiate between these stimuli, untrained participants rate them similarly, despite their differences. This confusion has created additional barriers in understanding the mechanism of astringent perception, which is currently debated. Understanding how to design experiments where untrained participants can clearly evaluate both sensations will lay the foundation to better understand astringency. One mechanism that is believed to contribute to astringency is the interaction of astringent stimuli with salivary proteins. Interestingly, the salivary protein profile may be influenced by consumption of fruits and vegetables. Therefore, the investigators will evaluate how bitter and astringent perceptions differ among high and low consumers of fruits and vegetables by collecting saliva following exposure to the stimuli. This knowledge will inform approaches to increase the appeal of healthy food.
Primary Outcome
Liking and flavor intensity ratings on the general labeled magnitude scale
Interventions
- DIAGNOSTIC_TEST Astringency and bitterness perception
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2017-04-30 |
| Est. Completion | 2018-05-30 |
What the finished NCT03171402 record still lists
NCT03171402 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 92 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Astringency and bitterness perception is the first listed.
NCT03171402 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03171402 about?
NCT03171402 is a clinical study titled "Astringency and Bitterness Perception". The investigators are conducting a study to better understand how the average consumer differentiates between bitter and astringent sensations, both of which are typically unpleasant sensations characteristic of some healthy foods. Astringency is the dry/rough sensation elicited by foods such as gre...
What is the current status of trial NCT03171402?
This trial is currently completed. The enrollment target is 92 participants. The study started on 2017-04-30. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT03171402?
The interventions under investigation include: Astringency and bitterness perception (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03171402?
This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI